Does Puma Biotechnology's Approval Make It Worth More?

Does Puma Biotechnology's Approval Make It Worth More?


The company has secured an FDA go-ahead for its new breast cancer drug, but should investors still be buying its shares? roller-coaster ride to approval is finally over. After fits and starts in clinical trials, the FDA gave the company's breast cancer drug, Nerlynx, a green light, clearing the way to its commercialization later this year.



from Biotech News